Pharsight

Myovant Sciences patents expiration

1. Myfembree patents expiration

MYFEMBREE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(3 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9346822 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(4 months from now)

US11033551 MYOVANT SCIENCES Methods of treating uterine fibroids
Sep, 2037

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025
New Product (NP) May 26, 2024
M (M) Jan 27, 2026
New Indication (I) Aug 5, 2025

Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 26 May, 2021

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Dosage: TABLET;ORAL

More Information on Dosage

MYFEMBREE family patents

Family Patents

2. Orgovyx patents expiration

ORGOVYX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8058280 MYOVANT SCIENCES Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Jan, 2024

(3 months from now)

US7300935 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Jan, 2024

(3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735401 MYOVANT SCIENCES Thienopyrimidine compounds and use thereof
Feb, 2024

(4 months from now)

US10350170 MYOVANT SCIENCES Solid preparation
Feb, 2036

(12 years from now)

US10786501 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US10449191 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

US11583526 MYOVANT SCIENCES Treatment of prostate cancer
Sep, 2037

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2025

Drugs and Companies using RELUGOLIX ingredient

NCE-1 date: 2024-12-18

Market Authorisation Date: 18 December, 2020

Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORGOVYX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic